emc易倍官网入口Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • Media Resources
    • Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • emc易倍官网入口Financial Results
    • Annual Reports & Regulated Information
    • Investor Events & Financial Calendar
    • Shareholder Information
    • emc易倍官网入口Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • emc易倍官网入口Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • emc易倍官网入口Subscribe
  • Press shift tab to select search category
    Loading...
  • English  EN     Fran?ais  FR     EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • emc易倍官网入口Middle East & Africa
    • Brazil
    • Canada
    • United States
    • Mexico
    • emc易倍官网入口 Colombia
    • Australia
    • China
    • emc易倍官网入口 Singapore
    • South Korea
    • Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • France
    • Nordics
    • emc易倍官网入口 Greece
    • Italy
    • Netherlands
    • emc易倍官网入口 Spain
    • Poland
    • Russia
    • emc易倍官网入口 Czech Republic
    • Romania
    • emc易倍官网入口 Hungary
    • Slovakia
    • Switzerland
    • Austria
    • emc易倍官网入口 UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • emc易倍官网入口Leadership
    • History
    • Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • emc易倍官网入口Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • emc易倍官网入口Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • Lay Summaries
      • Find Clinical Trials
    • Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • emc易倍官网入口Patients
    • emc易倍官网入口Together for Oncology
    • Together for Rare Disease
    • emc易倍官网入口Together for Neuroscience
    • Collaborate with us
  • Stories

emc易倍官网入口

Previous
Next

emc易倍官网入口

This article or press release has no online content. Please download the associated documents for more information.

Attachment

  • 2026-08-27-Ipsen-Voting-rights

emc易倍官网入口

- 12 January 2021 - 1 mins read

This article or press release has no online content. Please download the associated documents for more information.

Attachment

  • 2026-08-27-Ipsen-Voting-rights

emc易倍官网入口

Previous
Next
Related stories
01 June 2021 1 mins read

Ipsen announces the launch of an Employee Shareholding Plan
See more stories

emc易倍官网入口

11 July 2024

Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for...
09 July 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
09 July 2024

Ipsen – June 2024 – Monthly information relative to the...
08 July 2024

Half-year statement of IPSEN liquidity agreement – 2024 06 30
02 July 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
02 July 2024

Ipsen expands collaboration and license agreement for development of Cabometyx?...
25 June 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
18 June 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
11 June 2024

IPSEN – Buy-back programme – Art 5 of MAR –...
10 June 2024

Ipsen’s Iqirvo? receives U.S. FDA accelerated approval as a first-in-class...

IPN price

€166.80

 €0.90 (0.54%)

  • Media Resources
  • Annual Report
  • Contacts
  • emc易倍官网入口 Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • emc易倍官网入口Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?







2026-08-27 17:45:53